carvedilol has been researched along with Auricular Fibrillation in 62 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol and N-acetyl cysteine (NAC) combination decreases inflammation, oxidative stress, and postoperative atrial fibrillation (POAF) rates more than metoprolol or carvedilol." | 9.19 | Oxidative status, inflammation, and postoperative atrial fibrillation with metoprolol vs carvedilol or carvedilol plus N-acetyl cysteine treatment. ( Akcay, S; Ceyhan, BM; Dogan, A; Erdogan, D; Icli, A; Okutan, H; Ozaydin, M; Peker, O; Sutcu, R; Uysal, BA; Varol, E; Yucel, H, 2014) |
| " Aim was to evaluate the efficacy of metoprolol, carvedilol, and carvedilol plus NAC on the prevention of post-operative atrial fibrillation (POAF)." | 9.17 | Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. ( Akcay, S; Dogan, A; Erdogan, D; Icli, A; Okutan, H; Ozaydin, M; Peker, O; Varol, E; Yucel, H, 2013) |
| "We investigated the efficacy of carvedilol for preventing the recurrence of atrial fibrillation and reducing QT prolongation induced by bepridil." | 9.17 | Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy. ( Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K, 2013) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 9.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Ninety patients who underwent cardioversion of persistent atrial fibrillation (AF) were randomized to bisoprolol 5 to 10 mg once daily or carvedilol 12." | 9.10 | Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. ( Anagnostopoulos, CE; Camm, AJ; Giazitzoglou, E; Karvouni, E; Katritsis, DG; Korovesis, S; Panagiotakos, DB; Paxinos, G, 2003) |
| "Fourteen digitalised patients diagnosed with heart failure (NYHA Functional class II) with idiopathic dilated cardiomyopathy in chronic established atrial fibrillation were administered carvedilol in addition to their anti-heart failure medications in an attempt to improve their heart rate control." | 9.09 | Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. ( Agarwal, AK; Venugopalan, P, 2001) |
| "A systematic review and meta-analysis was performed to evaluate the effects of carvedilol versus metoprolol on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting in randomized controlled trials." | 8.90 | Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting. ( Aradi, D; Beavers, CJ; Biondi-Zoccai, G; Brugts, J; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Gasparini, M; Komócsi, A; Lavie, CJ; Meier, P; Menezes, AR; O'Keefe, JH; Vorobcsuk, A, 2014) |
| "Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation." | 7.83 | Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. ( Akçay, M; Aslan, AN; Baştuğ, S; Bozkurt, E; Durmaz, T; Sari, C; Sari, SÖ, 2016) |
| "We hypothesized that carvedilol can effectively suppress autonomic nerve activity (ANA) in ambulatory dogs during sinus rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA." | 7.80 | Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs. ( Chen, PS; Choi, EK; Lin, SF; Oh, S; Shen, MJ, 2014) |
| "We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia." | 7.78 | In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012) |
| "Although carvedilol and bisoprolol are effective medicines for the treatment of patients with heart failure (HF), only a few reports have compared their effects." | 7.76 | Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. ( Hachiya, H; Haraguchi, G; Hirao, K; Inagaki, H; Isobe, M; Kawabata, M; Kimura, S; Konishi, M, 2010) |
| "Postoperative treatment with carvedilol following landiolol has the effect of preventing tachycardia during AF after coronary artery bypass grafting." | 7.75 | Postoperative treatment of carvedilol following low dose landiolol has preventive effect for atrial fibrillation after coronary artery bypass grafting. ( Kawamura, T; Namai, A; Sakurai, M; Yoshioka, I, 2009) |
| "Although all beta blockers appear to be effective in the prevention of postoperative atrial fibrillation (AF) following coronary artery bypass surgery (CABG), carvedilol was found to be much more effective than metoprolol in this respect as the current study clearly delineated." | 7.75 | Beta blockers for the prevention of atrial fibrillation after coronary artery bypass surgery: carvedilol versus metoprolol. ( Celik, M; Celik, T; Gunay, C; Isik, E; Iyisoy, A; Jata, B, 2009) |
| " The purpose of the present case cohort study compared the control group with no carvedilol administered and the other group of patients given carvedilol and determined whether postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting (CABG)." | 7.74 | Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting. ( Izumoto, H; Kawazoe, K; Okabayashi, H; Tsuboi, J, 2008) |
| " Objectives of the present study were to evaluate the feasibility, tolerability and safety of carvedilol therapy in a cohort of patients > 70 years of age with CHF and left ventricular ejection fraction < 40% with chronic atrial fibrillation." | 7.73 | Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol? ( Cioffi, G; De Feo, S; Del Sindaco, D; Opasich, C; Pulignano, G; Stefenelli, C; Tarantini, L, 2006) |
| " To evaluate the efficacy of each dosage regimen and the dose-response relationship, changes in 24-h mean HR (mHR) on Holter electrocardiograms from baseline to weeks 2, 4, and 6 were determined as primary endpoints." | 6.84 | Heart rate control by carvedilol in Japanese patients with chronic atrial fibrillation: The AF Carvedilol study. ( Atarashi, H; Fukuzawa, M; Inoue, H; Kimura, T; Okumura, K; Shiosakai, K; Yamashita, T, 2017) |
| "Telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive AF patients, despite a similar lowering of blood pressure." | 6.77 | A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. ( Carbotta, S; Cittadini, A; Di Michele, S; Galzerano, D; Gaudio, C; Lama, D; Paolisso, G; Tedesco, MA; Tuccillo, B, 2012) |
| "Bisoprolol was started at 1." | 6.76 | Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. ( Arisi, G; Caminiti, G; Iellamo, F; Madonna, M; Marazzi, G; Massaro, R; Righi, D; Rosano, GM; Volterrani, M, 2011) |
| "The carvedilol group was treated with mean daily dose of 46 +/- 9 mg and metoprolol group with mean daily dose of 93 +/- 11 mg." | 6.73 | Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. ( Alizadeh, A; Emkanjoo, Z; Fazelifar, AF; Ghafarinejad, MH; Givtaj, N; Haghjoo, M; Hashemi, MJ; Hosseini, S; Khamoushi, AJ; Sadr-Ameli, MA; Saravi, M, 2007) |
| "Metoprolol was started at 50 mg twice daily and carvedilol was started at 12." | 6.73 | Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. ( Acikel, S; Aydinalp, A; Bal, U; Bozbas, H; Gultekin, B; Muderrisoglu, H; Ozin, B; Saritas, B; Sezgin, A; Yildirir, A, 2008) |
| "Carvedilol is a non-selective adrenergic blocker with anti-inflammatory, antioxidant, and multiple cationic channel blocking properties." | 6.72 | Carvedilol versus Metoprolol for the prevention of atrial fibrillation after off-pump coronary bypass surgery: rationale and design of the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT). ( Hayashi, Y; Kamei, M; Kanmura, Y; Kuro, M; Morita, S, 2006) |
| "Carvedilol was associated with a significant reduction in POAF (relative risk [RR] 0." | 6.50 | Carvedilol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. ( Wang, HS; Wang, ZW; Yin, ZT, 2014) |
| " Therefore, oral loading with propafenone (as "pill-in-the-pocket" treatment of recent-onset atrial fibrillation) in a patient on concurrent carvedilol treatment may lead to a pharmacokinetic interaction, with high plasma levels of propafenone and potential drug-related adverse effects." | 5.36 | Atrial fibrillation: adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction. ( Biffi, M; Boriani, G; Diemberger, I; Domenichini, G; Martignani, C; Marziali, A, 2010) |
| "The datasets included in this pooling initiative were derived from 4 trials: CAPRICORN (Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction), OPTIMAAL (Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan), VALIANT (Valsartan in Acute Myocardial Infarction Trial), and EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study); EPHESUS was used for external validation." | 5.27 | Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. ( Abdul-Rahim, AH; Dickstein, K; Ferreira, JP; Girerd, N; Gregson, J; Latar, I; McMurray, JJV; Pfeffer, MA; Pitt, B; Rossignol, P; Sharma, A; Zannad, F, 2018) |
| "Carvedilol and N-acetyl cysteine (NAC) combination decreases inflammation, oxidative stress, and postoperative atrial fibrillation (POAF) rates more than metoprolol or carvedilol." | 5.19 | Oxidative status, inflammation, and postoperative atrial fibrillation with metoprolol vs carvedilol or carvedilol plus N-acetyl cysteine treatment. ( Akcay, S; Ceyhan, BM; Dogan, A; Erdogan, D; Icli, A; Okutan, H; Ozaydin, M; Peker, O; Sutcu, R; Uysal, BA; Varol, E; Yucel, H, 2014) |
| "The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated." | 5.17 | Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). ( Abu-Zeitone, A; Jons, C; Kutyifa, V; McNitt, S; Moss, AJ; Ruwald, AC; Ruwald, MH; Zareba, W, 2013) |
| "We investigated the efficacy of carvedilol for preventing the recurrence of atrial fibrillation and reducing QT prolongation induced by bepridil." | 5.17 | Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy. ( Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K, 2013) |
| " Aim was to evaluate the efficacy of metoprolol, carvedilol, and carvedilol plus NAC on the prevention of post-operative atrial fibrillation (POAF)." | 5.17 | Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. ( Akcay, S; Dogan, A; Erdogan, D; Icli, A; Okutan, H; Ozaydin, M; Peker, O; Varol, E; Yucel, H, 2013) |
| "This pharmacogenetic substudy of the prospective, double-blind, randomized CIBIS-ELD trial determined the impact of the β1-adrenoceptor Arg189Gly polymorphism on heart-rate responses to bisoprolol or carvedilol in elderly patients with heart failure (421 with sinus rhythm, 107 with atrial fibrillation)." | 5.16 | Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. ( Apostolović, S; Dimković, S; Düngen, HD; Edelmann, F; Eschenhagen, T; Gelbrich, G; Haverkamp, W; Lainščak, M; Nešković, AN; Rau, T; Waagstein, F, 2012) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 5.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Patients with chronic heart failure were randomized to treatment (double blind) with metoprolol 50 mg twice daily or carvedilol 25 mg twice daily in addition to standard therapy." | 5.10 | Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. ( Chan, SK; Fung, JW; Sanderson, JE; Yeung, LY, 2002) |
| "Ninety patients who underwent cardioversion of persistent atrial fibrillation (AF) were randomized to bisoprolol 5 to 10 mg once daily or carvedilol 12." | 5.10 | Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. ( Anagnostopoulos, CE; Camm, AJ; Giazitzoglou, E; Karvouni, E; Katritsis, DG; Korovesis, S; Panagiotakos, DB; Paxinos, G, 2003) |
| "Fourteen digitalised patients diagnosed with heart failure (NYHA Functional class II) with idiopathic dilated cardiomyopathy in chronic established atrial fibrillation were administered carvedilol in addition to their anti-heart failure medications in an attempt to improve their heart rate control." | 5.09 | Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. ( Agarwal, AK; Venugopalan, P, 2001) |
| "A systematic review and meta-analysis was performed to evaluate the effects of carvedilol versus metoprolol on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting in randomized controlled trials." | 4.90 | Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting. ( Aradi, D; Beavers, CJ; Biondi-Zoccai, G; Brugts, J; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Gasparini, M; Komócsi, A; Lavie, CJ; Meier, P; Menezes, AR; O'Keefe, JH; Vorobcsuk, A, 2014) |
| "Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation." | 3.83 | Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. ( Akçay, M; Aslan, AN; Baştuğ, S; Bozkurt, E; Durmaz, T; Sari, C; Sari, SÖ, 2016) |
| "We hypothesized that carvedilol can effectively suppress autonomic nerve activity (ANA) in ambulatory dogs during sinus rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA." | 3.80 | Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs. ( Chen, PS; Choi, EK; Lin, SF; Oh, S; Shen, MJ, 2014) |
| "We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia." | 3.78 | In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012) |
| "Although carvedilol and bisoprolol are effective medicines for the treatment of patients with heart failure (HF), only a few reports have compared their effects." | 3.76 | Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. ( Hachiya, H; Haraguchi, G; Hirao, K; Inagaki, H; Isobe, M; Kawabata, M; Kimura, S; Konishi, M, 2010) |
| "Postoperative treatment with carvedilol following landiolol has the effect of preventing tachycardia during AF after coronary artery bypass grafting." | 3.75 | Postoperative treatment of carvedilol following low dose landiolol has preventive effect for atrial fibrillation after coronary artery bypass grafting. ( Kawamura, T; Namai, A; Sakurai, M; Yoshioka, I, 2009) |
| "Although all beta blockers appear to be effective in the prevention of postoperative atrial fibrillation (AF) following coronary artery bypass surgery (CABG), carvedilol was found to be much more effective than metoprolol in this respect as the current study clearly delineated." | 3.75 | Beta blockers for the prevention of atrial fibrillation after coronary artery bypass surgery: carvedilol versus metoprolol. ( Celik, M; Celik, T; Gunay, C; Isik, E; Iyisoy, A; Jata, B, 2009) |
| " The purpose of the present case cohort study compared the control group with no carvedilol administered and the other group of patients given carvedilol and determined whether postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting (CABG)." | 3.74 | Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting. ( Izumoto, H; Kawazoe, K; Okabayashi, H; Tsuboi, J, 2008) |
| " Objectives of the present study were to evaluate the feasibility, tolerability and safety of carvedilol therapy in a cohort of patients > 70 years of age with CHF and left ventricular ejection fraction < 40% with chronic atrial fibrillation." | 3.73 | Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol? ( Cioffi, G; De Feo, S; Del Sindaco, D; Opasich, C; Pulignano, G; Stefenelli, C; Tarantini, L, 2006) |
| " To evaluate the efficacy of each dosage regimen and the dose-response relationship, changes in 24-h mean HR (mHR) on Holter electrocardiograms from baseline to weeks 2, 4, and 6 were determined as primary endpoints." | 2.84 | Heart rate control by carvedilol in Japanese patients with chronic atrial fibrillation: The AF Carvedilol study. ( Atarashi, H; Fukuzawa, M; Inoue, H; Kimura, T; Okumura, K; Shiosakai, K; Yamashita, T, 2017) |
| "Telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive AF patients, despite a similar lowering of blood pressure." | 2.77 | A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. ( Carbotta, S; Cittadini, A; Di Michele, S; Galzerano, D; Gaudio, C; Lama, D; Paolisso, G; Tedesco, MA; Tuccillo, B, 2012) |
| "Bisoprolol was started at 1." | 2.76 | Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. ( Arisi, G; Caminiti, G; Iellamo, F; Madonna, M; Marazzi, G; Massaro, R; Righi, D; Rosano, GM; Volterrani, M, 2011) |
| "Metoprolol was started at 50 mg twice daily and carvedilol was started at 12." | 2.73 | Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. ( Acikel, S; Aydinalp, A; Bal, U; Bozbas, H; Gultekin, B; Muderrisoglu, H; Ozin, B; Saritas, B; Sezgin, A; Yildirir, A, 2008) |
| "The carvedilol group was treated with mean daily dose of 46 +/- 9 mg and metoprolol group with mean daily dose of 93 +/- 11 mg." | 2.73 | Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. ( Alizadeh, A; Emkanjoo, Z; Fazelifar, AF; Ghafarinejad, MH; Givtaj, N; Haghjoo, M; Hashemi, MJ; Hosseini, S; Khamoushi, AJ; Sadr-Ameli, MA; Saravi, M, 2007) |
| "Carvedilol is a non-selective adrenergic blocker with anti-inflammatory, antioxidant, and multiple cationic channel blocking properties." | 2.72 | Carvedilol versus Metoprolol for the prevention of atrial fibrillation after off-pump coronary bypass surgery: rationale and design of the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT). ( Hayashi, Y; Kamei, M; Kanmura, Y; Kuro, M; Morita, S, 2006) |
| "Treatment with carvedilol compared with metoprolol offers additional benefits among patients with atrial fibrillation." | 2.71 | Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. ( Charlesworth, A; Cleland, J; Hanrath, P; Komajda, M; Metra, M; Olsson, LG; Poole-Wilson, P; Swedberg, K; Torp-Pedersen, C, 2005) |
| "Carvedilol was associated with a significant reduction in POAF (relative risk [RR] 0." | 2.50 | Carvedilol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. ( Wang, HS; Wang, ZW; Yin, ZT, 2014) |
| "Carvedilol vs metoprolol was also associated with a 16% reduction in the risk of fast VA." | 1.91 | Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients. ( Aktaş, MK; Chen, AY; Diamond, A; Goldenberg, I; Kutyifa, V; McNitt, S; Polonsky, B; Sampath, R; Steinberg, JS; Younis, A; Zareba, W, 2023) |
| "Different arrhythmias are cause of sudden death in many patients with heart failure." | 1.46 | THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS. ( Khintibidze, I; Tsetskhladze, E, 2017) |
| "In the treatment of a cardiogenic shock induced by β-blockers and/or non-dihydropyridine calcium channel blockers, administration of intravenous calcium, glucagon or high-dose insulin is recommended." | 1.43 | [Cardiogenic shock after drug therapy for atrial fibrillation with tachycardia : Case report of an 89-year-old woman]. ( Bertsch, T; Christ, M; Fey, H; Geise, AT; Jost, M, 2016) |
| " Therefore, oral loading with propafenone (as "pill-in-the-pocket" treatment of recent-onset atrial fibrillation) in a patient on concurrent carvedilol treatment may lead to a pharmacokinetic interaction, with high plasma levels of propafenone and potential drug-related adverse effects." | 1.36 | Atrial fibrillation: adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction. ( Biffi, M; Boriani, G; Diemberger, I; Domenichini, G; Martignani, C; Marziali, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (46.77) | 29.6817 |
| 2010's | 29 (46.77) | 24.3611 |
| 2020's | 4 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Stone, KH | 1 |
| Reynolds, K | 1 |
| Davis, S | 1 |
| Van Tassell, BW | 1 |
| Gibson, CM | 1 |
| Jalalian, R | 1 |
| Maleki, M | 1 |
| Ghafari, R | 1 |
| Habibi, V | 1 |
| Heydari, S | 1 |
| Iranian, M | 1 |
| Engin, M | 3 |
| Guvenc, O | 3 |
| Ata, F | 3 |
| Yavuz, S | 3 |
| Diamond, A | 1 |
| Goldenberg, I | 2 |
| Younis, A | 1 |
| Sampath, R | 1 |
| Kutyifa, V | 2 |
| Chen, AY | 1 |
| McNitt, S | 2 |
| Polonsky, B | 1 |
| Steinberg, JS | 1 |
| Zareba, W | 2 |
| Aktaş, MK | 1 |
| Irie, M | 1 |
| Tsuneoka, Y | 1 |
| Shimobayashi, M | 1 |
| Hasegawa, N | 1 |
| Tanaka, Y | 1 |
| Mochizuki, S | 1 |
| Ichige, S | 1 |
| Hamaguchi, S | 1 |
| Namekata, I | 1 |
| Tanaka, H | 1 |
| Tsetskhladze, E | 1 |
| Khintibidze, I | 1 |
| Ferreira, JP | 1 |
| Girerd, N | 1 |
| Gregson, J | 1 |
| Latar, I | 1 |
| Sharma, A | 1 |
| Pfeffer, MA | 1 |
| McMurray, JJV | 1 |
| Abdul-Rahim, AH | 1 |
| Pitt, B | 1 |
| Dickstein, K | 1 |
| Rossignol, P | 1 |
| Zannad, F | 1 |
| Franken, PR | 1 |
| Woltersdorf, R | 1 |
| Ruwald, MH | 1 |
| Abu-Zeitone, A | 1 |
| Jons, C | 1 |
| Ruwald, AC | 1 |
| Moss, AJ | 1 |
| Ulimoen, SR | 4 |
| Enger, S | 4 |
| Pripp, AH | 2 |
| Abdelnoor, M | 2 |
| Arnesen, H | 3 |
| Gjesdal, K | 2 |
| Tveit, A | 4 |
| DiNicolantonio, JJ | 1 |
| Beavers, CJ | 1 |
| Menezes, AR | 1 |
| Lavie, CJ | 1 |
| O'Keefe, JH | 1 |
| Meier, P | 1 |
| Vorobcsuk, A | 1 |
| Aradi, D | 1 |
| Komócsi, A | 1 |
| Chatterjee, S | 1 |
| D'Ascenzo, F | 1 |
| Gasparini, M | 1 |
| Brugts, J | 1 |
| Biondi-Zoccai, G | 1 |
| Nakamura, K | 1 |
| Fukami, N | 1 |
| Choi, EK | 1 |
| Shen, MJ | 1 |
| Lin, SF | 1 |
| Chen, PS | 1 |
| Oh, S | 1 |
| Ozaydin, M | 2 |
| Peker, O | 2 |
| Erdogan, D | 2 |
| Akcay, S | 2 |
| Yucel, H | 2 |
| Icli, A | 2 |
| Ceyhan, BM | 1 |
| Sutcu, R | 1 |
| Uysal, BA | 1 |
| Varol, E | 2 |
| Dogan, A | 2 |
| Okutan, H | 2 |
| Norseth, J | 2 |
| Wang, HS | 1 |
| Wang, ZW | 1 |
| Yin, ZT | 1 |
| Corino, VD | 1 |
| Mainardi, LT | 1 |
| Platonov, PG | 1 |
| Khand, AU | 2 |
| Chew, PG | 1 |
| Douglas, H | 1 |
| Jones, J | 1 |
| Jan, A | 1 |
| Cleland, JG | 4 |
| Hahn, L | 1 |
| Hahn, M | 1 |
| Fey, H | 1 |
| Jost, M | 1 |
| Geise, AT | 1 |
| Bertsch, T | 1 |
| Christ, M | 1 |
| Aslan, AN | 1 |
| Sari, C | 1 |
| Baştuğ, S | 1 |
| Sari, SÖ | 1 |
| Akçay, M | 1 |
| Durmaz, T | 1 |
| Bozkurt, E | 1 |
| Horjen, AW | 1 |
| Seljeflot, I | 1 |
| Inoue, H | 1 |
| Atarashi, H | 1 |
| Okumura, K | 1 |
| Yamashita, T | 1 |
| Fukuzawa, M | 1 |
| Shiosakai, K | 1 |
| Kimura, T | 1 |
| Banach, M | 1 |
| Mariscalco, G | 1 |
| Ugurlucan, M | 1 |
| Rysz, J | 1 |
| Boriani, G | 1 |
| Biffi, M | 1 |
| Diemberger, I | 1 |
| Domenichini, G | 1 |
| Marziali, A | 1 |
| Martignani, C | 1 |
| Yoshioka, I | 1 |
| Sakurai, M | 1 |
| Namai, A | 1 |
| Kawamura, T | 1 |
| Konishi, M | 1 |
| Haraguchi, G | 1 |
| Kimura, S | 1 |
| Inagaki, H | 1 |
| Kawabata, M | 1 |
| Hachiya, H | 1 |
| Hirao, K | 1 |
| Isobe, M | 1 |
| Zakirova, AN | 1 |
| Abdiukova, ER | 1 |
| Marazzi, G | 1 |
| Iellamo, F | 1 |
| Volterrani, M | 1 |
| Caminiti, G | 1 |
| Madonna, M | 1 |
| Arisi, G | 1 |
| Massaro, R | 1 |
| Righi, D | 1 |
| Rosano, GM | 1 |
| Kawaguchi, T | 1 |
| Takasugi, N | 1 |
| Kubota, T | 1 |
| Takasugi, M | 1 |
| Kanamori, H | 1 |
| Ushikoshi, H | 1 |
| Hattori, A | 1 |
| Aoyama, T | 1 |
| Kawasaki, M | 1 |
| Nishigaki, K | 1 |
| Takemura, G | 1 |
| Minatoguchi, S | 1 |
| Verrier, RL | 1 |
| Galzerano, D | 1 |
| Di Michele, S | 1 |
| Paolisso, G | 1 |
| Tuccillo, B | 1 |
| Lama, D | 1 |
| Carbotta, S | 1 |
| Cittadini, A | 1 |
| Tedesco, MA | 1 |
| Gaudio, C | 1 |
| Rau, T | 1 |
| Düngen, HD | 1 |
| Edelmann, F | 1 |
| Waagstein, F | 1 |
| Lainščak, M | 1 |
| Dimković, S | 1 |
| Apostolović, S | 1 |
| Nešković, AN | 1 |
| Haverkamp, W | 1 |
| Gelbrich, G | 1 |
| Eschenhagen, T | 2 |
| Kawamura, M | 1 |
| Munetsugu, Y | 1 |
| Tanno, K | 1 |
| Kobayashi, Y | 1 |
| Fung, JW | 1 |
| Chan, SK | 1 |
| Yeung, LY | 1 |
| Sanderson, JE | 1 |
| Deedwania, PC | 1 |
| Merritt, JC | 1 |
| Niebauer, M | 1 |
| Tarakji, K | 1 |
| Hammer, D | 1 |
| Mills, RM | 1 |
| Katritsis, DG | 3 |
| Panagiotakos, DB | 1 |
| Karvouni, E | 1 |
| Giazitzoglou, E | 1 |
| Korovesis, S | 1 |
| Paxinos, G | 1 |
| Anagnostopoulos, CE | 1 |
| Camm, AJ | 1 |
| Ramaswamy, K | 2 |
| Gheorghiade, M | 1 |
| Lukas, MA | 2 |
| Kanoupakis, EM | 1 |
| Manios, EG | 1 |
| Mavrakis, HE | 1 |
| Tzerakis, PG | 1 |
| Mouloudi, HK | 1 |
| Vardas, PE | 1 |
| Swedberg, K | 2 |
| Olsson, LG | 1 |
| Charlesworth, A | 1 |
| Cleland, J | 1 |
| Hanrath, P | 1 |
| Komajda, M | 2 |
| Metra, M | 2 |
| Torp-Pedersen, C | 2 |
| Poole-Wilson, P | 1 |
| Opasich, C | 2 |
| De Feo, S | 2 |
| Cioffi, G | 2 |
| Pulignano, G | 2 |
| Del Sindaco, D | 2 |
| Tarantini, L | 2 |
| Gualco, A | 1 |
| Patrignani, A | 1 |
| Naccarelli, GV | 2 |
| Kowey, PR | 1 |
| Okumura, Y | 1 |
| Watanabe, I | 1 |
| Nakai, T | 1 |
| Sugimura, H | 1 |
| Hashimoto, K | 1 |
| Masaki, R | 1 |
| Ohkubo, K | 1 |
| Takagi, Y | 1 |
| Shindo, A | 1 |
| Ozawa, Y | 1 |
| Saito, S | 1 |
| Kanmatsuse, K | 1 |
| Stefenelli, C | 1 |
| Kamei, M | 1 |
| Morita, S | 1 |
| Hayashi, Y | 1 |
| Kanmura, Y | 1 |
| Kuro, M | 1 |
| Hohnloser, SH | 1 |
| Dorian, P | 1 |
| Roberts, R | 1 |
| Gent, M | 1 |
| Israel, CW | 1 |
| Fain, E | 1 |
| Champagne, J | 1 |
| Connolly, SJ | 1 |
| Patanè, S | 1 |
| Marte, F | 1 |
| Di Bella, G | 1 |
| Acikel, S | 1 |
| Bozbas, H | 1 |
| Gultekin, B | 1 |
| Aydinalp, A | 1 |
| Saritas, B | 1 |
| Bal, U | 1 |
| Yildirir, A | 1 |
| Muderrisoglu, H | 1 |
| Sezgin, A | 1 |
| Ozin, B | 1 |
| Spark, P | 1 |
| Moullet, C | 1 |
| Scherhag, A | 1 |
| Remme, W | 1 |
| Di Lenarda, A | 1 |
| Poole-Wilson, PA | 1 |
| Wolbrette, DL | 1 |
| Samii, S | 1 |
| Banchs, JE | 1 |
| Penny-Peterson, E | 1 |
| Gonzalez, MD | 1 |
| Haghjoo, M | 1 |
| Saravi, M | 1 |
| Hashemi, MJ | 1 |
| Hosseini, S | 1 |
| Givtaj, N | 1 |
| Ghafarinejad, MH | 1 |
| Khamoushi, AJ | 1 |
| Emkanjoo, Z | 1 |
| Fazelifar, AF | 1 |
| Alizadeh, A | 1 |
| Sadr-Ameli, MA | 1 |
| Celik, T | 1 |
| Iyisoy, A | 1 |
| Jata, B | 1 |
| Celik, M | 1 |
| Gunay, C | 1 |
| Isik, E | 1 |
| Tsuboi, J | 1 |
| Kawazoe, K | 1 |
| Izumoto, H | 1 |
| Okabayashi, H | 1 |
| Louis, A | 1 |
| Crabbe, S | 1 |
| Ford, S | 1 |
| Thackray, S | 1 |
| Houghton, T | 1 |
| Clark, A | 1 |
| Agarwal, AK | 1 |
| Venugopalan, P | 1 |
| Joglar, JA | 1 |
| Acusta, AP | 1 |
| Shusterman, NH | 1 |
| Kowal, RC | 1 |
| Barbera, SJ | 1 |
| Hamdan, MH | 1 |
| Page, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy[NCT00180271] | 1,820 participants (Actual) | Interventional | 2004-12-31 | Completed | |||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| Rate Control in Atrial Fibrillation II[NCT02695992] | Phase 4 | 122 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Rate Control in Atrial Fibrillation[NCT00313157] | Phase 3 | 80 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure[NCT00878384] | 52 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980] | 500 participants (Anticipated) | Observational | 2015-01-01 | Recruiting | |||
| [NCT00257959] | Phase 4 | 400 participants | Interventional | 2001-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"MADIT-CRT was an event-driven trial in which patients were monitored for all-cause mortality and HF events. An HF event was defined as either hospitalization for symptoms and/or signs consistent with congestive HF and:~administration of intravenous decongestive therapy that does not involve formal in-patient hospital admission, regardless of the setting (i.e. in an emergency room setting, in the physician's office, etc.), or~administration of an augmented HF regimen with oral or intravenous medications during an in-hospital stay." (NCT00180271)
Timeframe: Outcome measured at average follow-up duration of 2.4 years.
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Patients who are Event Free | Patients with Death or Heart Failure Event | Patients with Heart Failure Event Alone | Patients with Death at Any Time | |
| Cardiac Resynchronization Therapy + Defibrillator | 901 | 188 | 152 | 74 |
| Implantable Cardioverter Defibrillator Alone | 543 | 188 | 170 | 53 |
8 reviews available for carvedilol and Auricular Fibrillation
| Article | Year |
|---|---|
Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting.
Topics: Adrenergic alpha-1 Receptor Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Ca | 2014 |
Carvedilol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carbazoles; Cardiac Surgical Procedures; Carvedilo | 2014 |
Prevention of and medical therapy for atrial arrhythmias in heart failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 2002 |
Role of carvedilol in atrial fibrillation: insights from clinical trials.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Carvedilol; Di | 2004 |
Antiadrenergic therapy in the control of atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Cardi | 2005 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
New antiarrhythmic treatment of atrial fibrillation.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythm | 2007 |
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cachexia; Carbazoles; Carboxylic Acids; Carvedilol | 2001 |
29 trials available for carvedilol and Auricular Fibrillation
| Article | Year |
|---|---|
Comparing the efficacy of N-acetylcysteine plus carvedilol versus carvedilol in the prevention of atrial fibrillation following coronary artery bypass graft surgery.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Atrial Fibrillation; Carvedilol; Coronary Artery Bypass | 2022 |
Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation.
Topics: Aged; Atrial Fibrillation; Carvedilol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocard | 2018 |
Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carb | 2013 |
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Carbazoles; Carved | 2014 |
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Carbazoles; Carved | 2014 |
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Carbazoles; Carved | 2014 |
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Carbazoles; Carved | 2014 |
Oxidative status, inflammation, and postoperative atrial fibrillation with metoprolol vs carvedilol or carvedilol plus N-acetyl cysteine treatment.
Topics: Acetylcysteine; Aged; Antihypertensive Agents; Atrial Fibrillation; Carbazoles; Cardiac Surgical Pro | 2014 |
Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Carbazoles; Carved | 2014 |
Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Carbazoles; Carved | 2014 |
Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Carbazoles; Carved | 2014 |
Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Carbazoles; Carved | 2014 |
Rate-control drugs affect variability and irregularity measures of RR intervals in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2015 |
The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Biomarkers; Carbazoles; Carvedilol; Case-Con | 2015 |
Troponin I levels in permanent atrial fibrillation-impact of rate control and exercise testing.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 2016 |
Heart rate control by carvedilol in Japanese patients with chronic atrial fibrillation: The AF Carvedilol study.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Carvedil | 2017 |
[Effect of beta-adrenoblockers on remodeling of myocardium and adhesive function of endothelium in patients with ischemic heart disease, complicated with chronic heart failure and atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Cell Adhesion Molecu | 2010 |
Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles | 2011 |
A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Atrial Fibrillation; Benzimidazoles; Benzoates; Carbazoles; Ca | 2012 |
Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles; Carvedilo | 2012 |
Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Bepridil; Biphenyl Compounds; Car | 2013 |
Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study.
Topics: Acetylcysteine; Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Carb | 2013 |
Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carved | 2002 |
Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles; Carvedilol; Double-B | 2003 |
Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Carvedilol; Electric Coun | 2004 |
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Double-Blind Method; | 2005 |
Recurrence of atrial fibrillation after internal cardioversion of persistent atrial fibrillation: prognostic importance of electrophysiologic parameters.
Topics: Action Potentials; Aged; Atrial Fibrillation; Bepridil; Carbazoles; Carvedilol; Electric Countershoc | 2005 |
Carvedilol versus Metoprolol for the prevention of atrial fibrillation after off-pump coronary bypass surgery: rationale and design of the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carved | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carved | 2008 |
The safety of amiodarone in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; | 2007 |
Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol | 2007 |
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cachexia; Carbazoles; Carboxylic Acids; Carvedilol | 2001 |
Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Atrial Fibrillation; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Digitalis Glycosi | 2001 |
Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program.
Topics: Adrenergic alpha-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Double-Blind Method | 2001 |
26 other studies available for carvedilol and Auricular Fibrillation
| Article | Year |
|---|---|
Comparison of new-onset post-operative atrial fibrillation between patients receiving carvedilol and metoprolol after off-pump coronary artery bypass graft surgery.
Topics: Adrenergic beta-Antagonists; Adult; Atrial Fibrillation; Bradycardia; Carvedilol; Coronary Artery By | 2023 |
Diagnosis of new-onset postoperative atrial fibrillation is important.
Topics: Atrial Fibrillation; Carvedilol; Coronary Artery Bypass, Off-Pump; Humans; Metoprolol; Risk Factors | 2023 |
Diagnosis of new-onset postoperative atrial fibrillation is important.
Topics: Atrial Fibrillation; Carvedilol; Coronary Artery Bypass, Off-Pump; Humans; Metoprolol; Risk Factors | 2023 |
Diagnosis of new-onset postoperative atrial fibrillation is important.
Topics: Atrial Fibrillation; Carvedilol; Coronary Artery Bypass, Off-Pump; Humans; Metoprolol; Risk Factors | 2023 |
Diagnosis of new-onset postoperative atrial fibrillation is important.
Topics: Atrial Fibrillation; Carvedilol; Coronary Artery Bypass, Off-Pump; Humans; Metoprolol; Risk Factors | 2023 |
Diagnosis of new-onset postoperative atrial fibrillation is important.
Topics: Atrial Fibrillation; Carvedilol; Coronary Artery Bypass, Off-Pump; Humans; Metoprolol; Risk Factors | 2023 |
Diagnosis of new-onset postoperative atrial fibrillation is important.
Topics: Atrial Fibrillation; Carvedilol; Coronary Artery Bypass, Off-Pump; Humans; Metoprolol; Risk Factors | 2023 |
Diagnosis of new-onset postoperative atrial fibrillation is important.
Topics: Atrial Fibrillation; Carvedilol; Coronary Artery Bypass, Off-Pump; Humans; Metoprolol; Risk Factors | 2023 |
Diagnosis of new-onset postoperative atrial fibrillation is important.
Topics: Atrial Fibrillation; Carvedilol; Coronary Artery Bypass, Off-Pump; Humans; Metoprolol; Risk Factors | 2023 |
Diagnosis of new-onset postoperative atrial fibrillation is important.
Topics: Atrial Fibrillation; Carvedilol; Coronary Artery Bypass, Off-Pump; Humans; Metoprolol; Risk Factors | 2023 |
Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carvedilol; Defibrillators, Implantable; Heart Fai | 2023 |
Involvement of alpha- and beta-adrenoceptors in the automaticity of the isolated guinea pig pulmonary vein myocardium.
Topics: Animals; Atenolol; Atrial Fibrillation; Carbazoles; Carvedilol; Guinea Pigs; In Vitro Techniques; Ma | 2017 |
THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2017 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Altered responses to vasopressors of a patient medicated with carvedilol, pilsicainide and enalapril.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atria | 2014 |
Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs.
Topics: Administration, Oral; Adrenergic alpha-2 Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Atri | 2014 |
Carvedilol-induced hyperkalemia in a patient with chronic kidney disease.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Dose-Response Relati | 2015 |
[Cardiogenic shock after drug therapy for atrial fibrillation with tachycardia : Case report of an 89-year-old woman].
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Critical Care; Drug Interactions; Dr | 2016 |
Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban.
Topics: Aged; Anticoagulants; Antihypertensive Agents; Atrial Fibrillation; Carbazoles; Carvedilol; Cholesta | 2016 |
Letter by Banach et al regarding article, "postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting".
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carbazoles; Carvedilol; Coronary Artery Bypass; Co | 2008 |
Atrial fibrillation: adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Carvedilol; Dr | 2010 |
Postoperative treatment of carvedilol following low dose landiolol has preventive effect for atrial fibrillation after coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carbazoles; Carvedilol; Coronary Artery Bypass; Fe | 2009 |
Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Bisoprolol; Carbazoles; C | 2010 |
In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Carbazoles; Carv | 2012 |
A frequent gene polymorphism affecting the heart-rate response to carvedilol.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carbazoles; Carvedilol; Dose-Response Relationship | 2013 |
Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Carbazoles; Carvedilol; Coronary | 2003 |
Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carbazoles; Carvedilol; Heart Failure; Humans; Pro | 2003 |
Anti-inflammatory medication for atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Atrial Fibrillation; Bisoprolol; Carbazoles; | 2004 |
Does atrial fibrillation in elderly patients with chronic heart failure limit the efficacy of carvedilol? Suggestions from an observational study.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Atrial Fibr | 2005 |
Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; C | 2006 |
Transient syncope, left bundle branch block and first degree atrioventricular block after "pill-in-the-pocket" administration.
Topics: Aged; Atrial Fibrillation; Atrioventricular Block; Bundle-Branch Block; Carbazoles; Carvedilol; Drug | 2008 |
Beta blockers for the prevention of atrial fibrillation after coronary artery bypass surgery: carvedilol versus metoprolol.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carbazoles; Carvedilol; Coronary Artery Bypass; Hu | 2009 |
Carvedilol is more effective than metoprolol in preventing atrial fibrillation (AF) after coronary artery bypass.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol | 2008 |
Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Case-Control Studies | 2008 |